

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Astrum Financial Holdings Limited**  
**阿仕特朗金融控股有限公司**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 8333)**

**DISCLOSEABLE TRANSACTION:  
APPLICATION FOR SHARES IN THE IPO OF  
JD HEALTH INTERNATIONAL INC.**

On 1 December 2020, the Company placed the Order through Astrum Capital for the application to subscribe for 80,000 JD Health Shares with a total application money of approximately HK\$5.7 million (including brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

As one of the applicable percentage ratios for the Application exceeds 5% but is less than 25%, the Application constitutes a discloseable transaction of the Company and is subject to the reporting and announcement requirements under Chapter 19 of the GEM Listing Rules.

**THE APPLICATION**

The Board hereby announces that on 1 December 2020, the Company placed the Order through Astrum Capital for the application to subscribe for 80,000 JD Health Shares with a total application money of approximately HK\$5.7 million (including brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

**Offer price**

The offer price of each JD Health Share shall be in the range of HK\$62.80 to HK\$70.58. According to the IPO timetable as disclosed in the Prospectus, the final offer price of each JD Health Share will be announced on 7 December 2020.

## Allotment results of the Application

The completion of the Order is subject to the successful listing of JD Health Shares on the Stock Exchange and final allocation of the JD Health Shares. The Company may or may not be allocated with any JD Health Shares in the IPO. According to the IPO timetable as disclosed in the Prospectus, JD Health will announce the allotment results on 7 December 2020 and the expected listing date of JD Health is 8 December 2020. The Company will issue a further announcement in respect of the allotment results of the Application when the Order is materialized and completed.

## INFORMATION OF THE GROUP

The Group is principally engaged in the provision of brokerage services, placing and underwriting services, corporate finance advisory services, financing services including securities and initial public offering financing, and asset management services.

## INFORMATION OF JD Health

According to the Prospectus, JD Health engage in a comprehensive “Internet + healthcare” ecosystem, providing pharmaceutical and healthcare products, internet healthcare, health management, intelligent healthcare solutions to the customers, and a variety of marketing services to the business partners. For further details of the business of JD Health, please refer to the Prospectus, which has been published on the website of the Stock Exchange on 26 November 2020.

Set out below are certain audited consolidated financial information of JD Health for the financial years ended 31 December 2017, 31 December 2018 and 31 December 2019 as disclosed in the Prospectus:

	<b>For the year ended 31 December</b>		
	<b>2017</b>	<b>2018</b>	<b>2019</b>
	<i>(RMB'000)</i>	<i>(RMB'000)</i>	<i>(RMB'000)</i>
Profit/(loss) before tax	255,979	306,232	(834,700)
Profit/(loss) for the year	178,534	214,927	(971,805)

  

	<b>As of 31 December</b>		
	<b>2017</b>	<b>2018</b>	<b>2019</b>
	<i>(RMB'000)</i>	<i>(RMB'000)</i>	<i>(RMB'000)</i>
Total assets	911,363	1,182,147	8,676,677
Total equity	662,624	749,221	(459,031)

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, JD Health and its controlling shareholders are third parties independent of the Company and its connected persons.

## **REASONS FOR AND BENEFITS OF THE APPLICATION**

According to the Prospectus, JD Health is the largest online healthcare platform by revenue in China in 2019, recording a total revenue of RMB10.8 billion. JD Health provide comprehensive online healthcare services, such as online consultation and prescription renewal, chronic disease management, family doctor and consumer healthcare. These services are offered on a 24/7 basis. JD Health has assembled a team of in-house doctors and external medical professionals across departments and specialties and partnered with numerous third-party hospitals and healthcare institutions. JD Health is also the largest online retail pharmacy by revenue in China in 2019 with a market share of 29.8%. JD Health has established a supply chain network with industry-leading pharmaceutical companies and healthcare product suppliers.

Having considered the business prospects, financial performance and potential growth of JD Health as disclosed in the Prospectus, the Directors consider that the investment in JD Health Shares would enable the Group to diversify its investment portfolio and capture potential investment returns for the Group.

The Directors consider that the terms of the Order and the Application are on normal commercial terms and are fair and reasonable and the Application is in the interests of the Company and its Shareholders as a whole.

## **LISTING RULES REQUIREMENTS**

As one of the applicable percentage ratios for the Application exceeds 5% but is less than 25%, the Application constitutes a discloseable transaction of the Company and is subject to the reporting and announcement requirements under Chapter 19 of the GEM Listing Rules.

## DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

“JD Health”	JD Health International Inc. (東京健康股份有限公司), a company incorporated in the Cayman Islands as an exempted company with limited liability and the ordinary shares of which is expected to be listed and traded on the Main Board of the Stock Exchange (Stock code: 6618)
“JD Health Share(s)”	the ordinary share(s) with nominal value of US\$0.0000005 each in the share capital of JD Health to be traded in Hong Kong dollars and listed on the Stock Exchange
“Application”	the application to subscribe for 80,000 JD Health Shares by the Company pursuant to the Order
“Astrum Capital”	Astrum Capital Management Limited (阿仕特朗資本管理有限公司), a corporation licensed by the SFC to carry out Type 1 (dealing in securities), Type 2 (dealing in futures contracts), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities under the SFO and an indirect wholly-owned subsidiary of the Company
“Company”	Astrum Financial Holdings Limited (阿仕特朗金融控股有限公司), a company incorporated in the Cayman Islands as an exempted company with limited liability and the issued Shares of which are listed on GEM (stock code: 8333)
“connected person(s)”	has the meaning ascribed thereto under the GEM Listing Rules
“Director(s)”	the director(s) of the Company
“GEM”	GEM operated by the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on the GEM

“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“IPO”	initial public offering of JD Health Shares
“Order”	the order placed by the Company through Astrum Capital on 1 December 2020 for the application to subscribe for 80,000 JD Health Shares with a total application money of approximately HK\$5.7 million (including brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%)
“PRC”	the People’s Republic of China, and for the purposes of this announcement, excluding Hong Kong, the Macau Special Administrative Region and Taiwan
“Prospectus”	the prospectus of JD Health dated 26 November 2020
“SFC”	The Securities and Futures Commission of Hong Kong
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Shareholders”	shareholders of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By order of the Board  
**ASTRUM FINANCIAL HOLDINGS LIMITED**  
**Pan Chik**  
*Chairman and Chief Executive Officer*

Hong Kong, 1 December 2020

*As at the date of this announcement, the Directors are:*

***Executive Directors***

*Mr. Pan Chik (Chairman and chief executive officer)*

*Mr. Kwan Chun Yee Hidulf*

***Independent Non-executive Directors***

*Mr. Sum Loong*

*Mr. Lee Tak Cheung Vincent*

*Mr. Lau Hon Kee*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited ([www.hkexnews.hk](http://www.hkexnews.hk)) for at least 7 days from the date of its publication and on the website of the Company ([www.astrum-capital.com](http://www.astrum-capital.com)).*